Michael Seaman

Michael Seaman, Ph.D.

Michael Seaman, Ph.D.

Principal Investigator
Seaman Laboratory

Associate Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School

mseaman@bidmc.harvard.edu
T: 617-735-4449
F: 617-735-4540

Education

  • University of Washington, Seattle, WA, B.S., 1992 (Microbiology)
  • University of Texas Southwestern Medical Center, Dallas, TX, Ph.D., 2000 (Immunology)

Training

  • Research Fellow, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA, 2004 (Immunology)

Appointments

  • 1992-1994, Research Assistant I and II, Department of Immunobiology, Immunex Corporation, Seattle, WA
  • 2004-2007, Instructor in Medicine, Harvard Medical School, Boston, MA
  • 2007-2017, Assistant Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
  • 2017- present, Associate Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Honors

  • 1996-1999, NRSA Predoctoral Trainee, NIH #5 T32 CA09082
  • 2000-2002, NRSA Fellow, Postdoctoral Training Program in AIDS Research (Dana-Farber Cancer Institute, NIH #5 T32 AI07386)
  • 2008, Network Citizenship Award, NIH HIV Vaccine Trials Network (HVTN)
  • 2012, Young/Early Career Investigator Award, Collaboration for AIDS Vaccine Development (CAVD)

Publications

  • Williams WB, Alam SM, Ofek G, Erdmann N, Montefiori DC, Seaman MS, Wagh K, Korber B, Edwards RJ, Mansouri K, Eaton A, Cain DW, Martin M, Hwang J, Arus-Altuz A, Lu X, Cai F, Jamieson N, Parks R, Barr M, Foulger A, Anasti K, Patel P, Sammour S, Parsons RJ, Huang X, Lindenberger J, Fetics S, Janowska K, Niyongabo A, Janus BM, Astavans A, Fox CB, Mohanty I, Evangelous T, Chen Y, Berry M, Kirshner H, Van Itallie E, Saunders KO, Wiehe K, Cohen KW, McElrath MJ, Corey L, Acharya P, Walsh SR, Baden LR, Haynes BF. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans. Cell. 2024 May 14:S0092-8674(24)00459-8. doi: 10.1016/j.cell.2024.04.033. Epub ahead of print. PMID: 38761800. [Article]

  • Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S; HVTN 124 Study Team. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial. Lancet HIV. 2024 May;11(5):e285-e299. doi: 10.1016/S2352-3018(24)00036-5. PMID: 38692824. [Article]

  • Joshi VR, Claiborne DT, Pack ML, Power KA, Newman RM, Batorsky R, Bean DJ, Goroff MS, Lingwood D, Seaman MS, Rosenberg E, Allen TM.2024.A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. J Virol98:e01720-23.https://doi.org/10.1128/jvi.01720-23 [Article]

  • Lim SY, Lee J, Osuna CE, Vikhe P, Schalk DR, Chen E, Fray E, Kumar M, Schultz-Darken N, Rakasz E, Capuano S, Ladd RA, Gil HM, Evans DT, Jeng EK, Seaman M, Martin M, Van Dorp C, Perelson AS, Wong HC, Siliciano JD, Siliciano R, Safrit JT, Nixon DF, Soon-Shiong P, Nussenzweig M, Whitney JB. Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques. Science. 2024 Mar 8;383(6687):1104-1111. doi: 10.1126/science.adf7966. Epub 2024 Feb 29. PMID: 38422185; PMCID: PMC11022498. [Article]

  • Joshi VR, Claiborne DT, Pack ML, Power KA, Newman RM, Batorsky R, Bean DJ, Goroff MS, Lingwood D, Seaman MS, Rosenberg E, Allen TM.2024.A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. J Virol98:e01720-23.https://doi.org/10.1128/jvi.01720-23 [Article]

  • Li Y, Choudhary MC, Regan J, Boucau J, Nathan A, Speidel T, Liew MY, Edelstein GE, Kawano Y, Uddin R, Deo R, Marino C, Getz MA, Reynolds Z, Barry M, Gilbert RF, Tien D, Sagar S, Vyas TD, Flynn JP, Hammond SP, Novack LA, Choi B, Cernadas M, Wallace ZS, Sparks JA, Vyas JM, Seaman MS, Gaiha GD, Siedner MJ, Barczak AK, Lemieux JE, Li JZ. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci Transl Med. 2024 Jan 24;16(731):eadk1599. doi: 10.1126/scitranslmed.adk1599. Epub 2024 Jan 24. PMID: 38266109. [Article]

  • Mabrouk MT, Zidan AA, Aly N, Mohammed MT, Ghantous F, Seaman MS, Lovell JF, Nasr ML. Circularized Nanodiscs for Multivalent Mosaic Display of SARS-CoV-2 Spike Protein Antigens. Vaccines (Basel). 2023 Oct 28;11(11):1655. doi: 10.3390/vaccines11111655. PMID: 38005987; PMCID: PMC10675430. [Article]

  • Aid M, Sciacca M, McMahan K, Hope D, Liu J, Jacob-Dolan C, Powers O, Barrett J, Wu C, Mutoni A, Murdza T, Richter H, Velasco J, Teow E, Boursiquot M, Cook A, Orekov T, Hamilton M, Pessaint L, Ryan A, Hayes T, Martinot AJ, Seaman MS, Lewis MG, Andersen H, Barouch DH. Mpox infection protects against re-challenge in rhesus macaques. Cell. 2023 Oct 12;186(21):4652-4661.e13. doi: 10.1016/j.cell.2023.08.023. Epub 2023 Sep 20. PMID: 37734373; PMCID: PMC10591870. [Article]

  • Liew MY, Mathews JI, Li A, Singh R, Jaramillo SA, Weiss ZF, Bowman K, Ankomah PO, Ghantous F, Lewis GD, Neuringer I, Bitar N, Lipiner T, Dighe AS, Kotton CN, Seaman MS, Lemieux JE, Goldberg MB. Delayed and Attenuated Antibody Responses to Coronavirus Disease 2019 Vaccination With Poor Cross-Variant Neutralization in Solid-Organ Transplant Recipients-A Prospective Longitudinal Study. Open Forum Infect Dis. 2023 Aug 10;10(8):ofad369. doi: 10.1093/ofid/ofad369. PMID: 37577118; PMCID: PMC10414143. [Article]

  • Wagh K, Seaman MS. Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage. Curr Opin HIV AIDS. 2023 Jul 1;18(4):164-170. doi: 10.1097/COH.0000000000000800. Epub 2023 May 19. PMID: 37249911; PMCID: PMC10256304. [Article]